The top-ten therapeutic groups (at ATC-level 4) accounted for 33% of total costs to the national health system of prescriptions dispensed in pharmacies over the period December 2020 – November 2021, according to analysis by Diariofarma based on Ministry of Health data.
Oral blood glucose lowering drugs was the top-selling therapeutic group (at ATC-level 4) by value with sales totalling €642 million, followed by direct factor Xa inhibitors and HMG CoA reductase inhibitors. Total sales of the top-ten ATC-level 4 groups by value reached €4,432 million.
In terms of volume, proton pump inhibitors were the top-selling therapeutic group (at ATC-level 4) with more than 70 million units dispensed. HMG CoA reductase inhibitors and benzodiazepine derivatives took second and third places.
Source:
www.diariofarma.com, “El top-10 de grupos ATC-4 supone la tercera parte de la factura de recetas”, 7th February 2022